Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins FLT3 D835F||acute myeloid leukemia||predicted - sensitive||Crenolanib||Preclinical - Patient cell culture||Actionable||In a preclinical study, Crenolanib inhibited growth of blasts derived from a patient with acute myeloid leukemia harboring FLT3 internal tandem duplication (ITD) and FLT3 D835F (PMID: 24227820).||24227820|
|FLT3 exon 14 ins FLT3 D835F||Advanced Solid Tumor||sensitive||MRX-2843||Preclinical - Cell culture||Actionable||In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835F in culture (PMID: 27158668).||27158668|
|FLT3 exon 14 ins FLT3 D835F||acute myeloid leukemia||predicted - resistant||Sorafenib||Case Reports/Case Series||Actionable||In a clinical case study, FLT3 D835F was identified as an acquired resistance mutation in a patient with acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD) whose disease progressed on Nexavar (sorafenib) after initial response (PMID: 24227820).||24227820|
|FLT3 exon 14 ins FLT3 D835F||Advanced Solid Tumor||resistant||Pexidartinib||Preclinical||Actionable||In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835F were resistant to PLX3397 in culture (PMID: 25847190).||25847190|
|FLT3 exon 14 ins FLT3 D835F||hematologic cancer||sensitive||KX2-391||Preclinical - Cell culture||Actionable||In a preclinical study, KX2-391 treatment inhibited cell viability and decreased downstream signaling in cells expressing a FLT3-ITD mutation with FLT3 D835F in culture (PMID: 34217323).||34217323|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|